Venture Investors
Venture Investors is a Midwest-based venture capital firm that funds seed, early, and growth-stage startups and provides incubation financing. It concentrates on university technology transfer opportunities, particularly in the Midwest, and invests across healthcare, life sciences, agriculture, technology, clean tech, materials, energy, and hardware, including software and digital health. The firm backs companies licensed to research universities, including institutions such as the University of Wisconsin–Madison, and seeks opportunities with significant market potential and solid fundamentals. Seed investments typically range from 0.25 million to 2.5 million, with larger follow-ons possible, and the firm aims to lead rounds while also co-investing. It favors preferred equity and/or debt with warrant coverage and pursues exits through initial public offerings or sales after about five to seven years. Established in 1982, Venture Investors is headquartered in Madison, Wisconsin, with additional offices in Ann Arbor, Michigan, and Milwaukee, Wisconsin.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Minnesota
HistoSonics
Series D in 2024
HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.
HistoSonics
Convertible Note in 2022
HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.
HistoSonics
Series C in 2020
HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.
HistoSonics
Series C in 2019
HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.
HistoSonics
Series B in 2017
HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.
HistoSonics
Series A in 2014
HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.
Celleration
Series E in 2011
Celleration Inc. is a privately held medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, utilizes low-frequency ultrasound delivered through a saline mist to promote healing in wounds. This innovative approach allows ultrasound energy to penetrate beyond the surface of the wound, stimulating cellular activity and enhancing the healing process. Since receiving FDA clearance in 2005, Celleration has established a strong presence in the U.S. market, with over 1 million MIST Therapy treatments performed, benefiting more than 65,000 patients across numerous healthcare facilities. Celleration's commitment to advancing wound care technology has resulted in significant clinical and economic benefits, reinforcing its role in the medical community.
HistoSonics
Series A in 2010
HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.
Celleration
Series B in 2002
Celleration Inc. is a privately held medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, utilizes low-frequency ultrasound delivered through a saline mist to promote healing in wounds. This innovative approach allows ultrasound energy to penetrate beyond the surface of the wound, stimulating cellular activity and enhancing the healing process. Since receiving FDA clearance in 2005, Celleration has established a strong presence in the U.S. market, with over 1 million MIST Therapy treatments performed, benefiting more than 65,000 patients across numerous healthcare facilities. Celleration's commitment to advancing wound care technology has resulted in significant clinical and economic benefits, reinforcing its role in the medical community.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.